デュシェンヌ型筋ジストロフィー治療薬の世界市場レポート 2025年

デュシェンヌ型筋ジストロフィー（DMD）治療薬の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.8%で54億2,000万米ドルに成長します。予測期間の成長は、初期段階のバイオテクノロジー参入企業の増加、実臨床エビデンスと市販後データの増加、医療支出の増加、早期介入治療への需要の高まり、適応外コルチコステロイド使用の拡大などに起因すると考えられます。この期間の主な動向としては、バイオテクノロジーによる技術革新の急増、デジタルヘルスとウェアラブル技術の統合、個別化治療と変異特異的治療への関心の高まり、遺伝子治療とCRISPR技術の進歩などが挙げられます。

個別化医療への注目の高まりは、デュシェンヌ型筋ジストロフィー（DMD）治療薬市場の成長を大きく牽引すると予想されます。個別化医療は、遺伝的、環境的、ライフスタイル的要因に基づいて個々の患者に合わせた治療を行い、転帰を最適化し、治療を強化するものです。個別化医療に対する需要の高まりは、ゲノム技術の進歩によるところが大きく、これにより遺伝的変異を正確に特定し、個々のニーズに合わせた治療法を開発できるようになりました。個別化医療は、遺伝子プロファイルに基づいた標的治療を提供し、治療をより効果的にすることで、DMD治療薬に利益をもたらします。また、特定の遺伝子変異に集中することで薬剤開発が容易になり、治療成績と患者ケア全体が改善されます。例えば、2024年2月、米国の非営利団体である個別化医療連合（PMC）は、米国食品医薬品局（FDA）が2023年に26の個別化新薬を承認したと報告しました。したがって、個別化医療の成長はDMD治療薬市場の主要な促進要因です。

デュシェンヌ型筋ジストロフィー（DMD）治療薬市場の主要企業は、筋力を向上させ、疾患の進行を遅らせ、患者の予後を改善するために、副腎皮質ステロイドなどの革新的なソリューションの開発に注力しています。副腎皮質ステロイドは、副腎から自然に分泌されるステロイドホルモンであり、炎症を抑え、免疫系を抑制する薬として合成されます。例えば、2024年3月、米国のバイオ医薬品会社であるカタリスト・ファーマシューティカルズは、2歳以上のDMD患者を対象としたFDA承認の治療薬であるアガムリー（バモロロン）経口懸濁液40mg/mLを発売しました。アガムリーは、副腎皮質ステロイド薬で、炎症を抑え、筋細胞膜を安定化させることにより、疾患の進行を遅らせる効果があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のデュシェンヌ型筋ジストロフィー治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のデュシェンヌ型筋ジストロフィー治療薬市場：成長率分析
• 世界のデュシェンヌ型筋ジストロフィー治療薬市場の実績：規模と成長、2019年～2024年
• 世界のデュシェンヌ型筋ジストロフィー治療薬市場の予測：規模と成長、2024年～2029年、2034年
• 世界のデュシェンヌ型筋ジストロフィー治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のデュシェンヌ型筋ジストロフィー治療薬市場：薬剤タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• エクソンスキッピング薬
• コルチコステロイド
• 遺伝子治療
• その他の薬物の種類
• 世界のデュシェンヌ型筋ジストロフィー治療薬市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 経口
• 注射剤
• 世界のデュシェンヌ型筋ジストロフィー治療薬市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のデュシェンヌ型筋ジストロフィー治療薬市場、エクソンスキッピング薬の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• エテプリルセン
• ゴロディルセン
• ヴィルトラルセン
• カシメルセン
• その他のエクソンスキッピング療法
• 世界のデュシェンヌ型筋ジストロフィー治療薬市場、コルチコステロイドの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• プレドニゾン
• デフラザコート
• その他のコルチコステロイド
• 世界のデュシェンヌ型筋ジストロフィー治療薬市場、遺伝子治療の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• マイクロジストロフィン遺伝子治療
• CRISPR/Cas9ベースの遺伝子編集
• 幹細胞を用いた遺伝子治療
• その他の遺伝子治療
• 世界のデュシェンヌ型筋ジストロフィー治療薬市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• ユートロフィンモジュレーター
• 抗炎症剤
• アンチセンスオリゴヌクレオチド
• ミオスタチン阻害剤
• その他の支持療法

第7章 地域別・国別分析

• 世界のデュシェンヌ型筋ジストロフィー治療薬市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のデュシェンヌ型筋ジストロフィー治療薬市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• デュシェンヌ型筋ジストロフィー治療薬市場：競合情勢
• デュシェンヌ型筋ジストロフィー治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Aurobindo Pharma Limited
• Italfarmaco S.p.A
• Sarepta Therapeutics Inc.
• PTC Therapeutics Inc.
• FibroGen Inc.
• Wave Life Sciences Ltd.
• Solid Biosciences Inc.
• NS Pharma
• Capricor Therapeutics Inc.
• Santhera Pharmaceuticals
• ReveraGen BioPharma
• Antisense Therapeutics Limited
• Catalyst Pharmaceuticals Inc.
• EspeRare Foundation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• デュシェンヌ型筋ジストロフィー治療薬市場2029年：新たな機会を提供する国
• デュシェンヌ型筋ジストロフィー治療薬市場2029年：新たな機会を提供するセグメント
• デュシェンヌ型筋ジストロフィー治療薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Duchenne muscular dystrophy (DMD) drugs are medications and therapies designed to manage and slow the progression of Duchenne muscular dystrophy, a genetic disorder that leads to muscle weakness and degeneration. These drugs target the underlying genetic mutations, improve muscle function, and enhance quality of life. The primary goal of these drugs is to preserve muscle strength, delay disease progression, and increase mobility in individuals with DMD.

The main types of drugs in the duchenne muscular dystrophy market include exon skipping drugs, corticosteroids, gene therapy, and other treatments. Exon skipping drugs are specialized therapies that enable the body to produce a functional, albeit shorter, version of the dystrophin protein by bypassing defective sections of the dystrophin gene during protein synthesis. These drugs are administered through oral and injectable routes, and they are distributed via several channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The Duchenne muscular dystrophy drugs market research report is one of a series of new reports from The Business Research Company that provides Duchenne muscular dystrophy drugs market statistics, including Duchenne muscular dystrophy drugs industry global market size, regional shares, competitors with a Duchenne muscular dystrophy drugs market share, detailed Duchenne muscular dystrophy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Duchenne muscular dystrophy drugs industry. This Duchenne muscular dystrophy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy (DMD) drug market size has grown rapidly in recent years. It will grow from $2.83 billion in 2024 to $3.23 billion in 2025 at a compound annual growth rate (CAGR) of 14.2%. The growth during the historic period can be attributed to advancements in diagnostic capabilities, the expansion of patient registries and data collection, a surge in demand for DMD treatments, a growing pipeline of clinical-stage therapies, and increased regulatory incentives.

The duchenne muscular dystrophy (DMD) drug market size is expected to see rapid growth in the next few years. It will grow to $5.42 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to the rise of early-stage biotech entrants, an increase in real-world evidence and post-marketing data, higher health expenditure, growing demand for early intervention treatments, and an expansion in off-label corticosteroid use. Major trends during this period include a surge in biotech innovation, the integration of digital health and wearable technology, growing interest in personalized and mutation-specific therapies, and advancements in gene therapy and CRISPR technologies.

The increasing focus on personalized medicine is expected to significantly drive the growth of the Duchenne muscular dystrophy (DMD) drugs market. Personalized medicine involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors, optimizing outcomes and enhancing care. The rising demand for personalized medicine is largely due to advancements in genomic technologies, which allow for the precise identification of genetic variations and the development of treatments tailored to individual needs. Personalized medicine benefits DMD drugs by offering targeted therapies based on genetic profiles, making treatments more effective. It also facilitates drug development by concentrating on specific genetic mutations, thus improving treatment outcomes and overall patient care. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a substantial increase from the 12 approved in 2022. Therefore, the growth of personalized medicine is a key driver of the DMD drugs market.

Leading companies in the Duchenne muscular dystrophy (DMD) drugs market are focusing on developing innovative solutions, such as corticosteroids, to improve muscle strength, slow disease progression, and enhance patient outcomes. Corticosteroids are steroid hormones naturally produced by the adrenal glands or synthesized as medications to reduce inflammation and suppress the immune system. For instance, in March 2024, Catalyst Pharmaceuticals, a US-based biopharmaceutical company, launched AGAMREE (vamorolone) oral suspension 40 mg/mL, an FDA-approved treatment for DMD in patients aged two and older. AGAMREE is a corticosteroid that works by reducing inflammation and stabilizing muscle cell membranes, which helps slow disease progression.

In July 2023, Catalyst Pharmaceuticals, a US-based biopharmaceutical company, acquired an exclusive North American license for vamorolone (AGAMREE), a DMD drug, from Santhera Pharmaceuticals for an undisclosed amount. This acquisition allows Catalyst Pharmaceuticals to expand its portfolio and offer a more effective treatment option for DMD patients, addressing the growing demand for safer and more targeted therapies. Santhera Pharmaceuticals, a Switzerland-based company, specializes in developing innovative therapies for Duchenne muscular dystrophy.

Major players in the duchenne muscular dystrophy drugs market are Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb, Novartis AG, GSK plc, Eli Lilly and Company, Aurobindo Pharma Limited, Italfarmaco S.p.A, Sarepta Therapeutics Inc., PTC Therapeutics Inc., FibroGen Inc., Wave Life Sciences Ltd., Solid Biosciences Inc., NS Pharma, Capricor Therapeutics Inc., Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc., EspeRare Foundation, Satellos Bioscience Inc.

North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Duchenne muscular dystrophy (DMD) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Duchenne muscular dystrophy (DMD) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Duchenne muscular dystrophy (DMD) drugs market consists of sales of utrophin modulators, anti-inflammatory agents and myostatin inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Duchenne Muscular Dystrophy Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on duchenne muscular dystrophy drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for duchenne muscular dystrophy drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The duchenne muscular dystrophy drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Exon Skipping Drugs; Corticosteroids; Gene Therapy; Other Drug Types
• 2) By Route Of Administration: Oral; Injectable
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) Exon Skipping Drugs: Eteplirsen; Golodirsen; Viltolarsen; Casimersen; Other Exon Skipping Therapies
• 2) Corticosteroids: Prednisone; Deflazacort; Other Corticosteroids
• 3) Gene Therapy: Micro-dystrophin Gene Therapy; CRISPR/Cas9-Based Gene Editing; Stem Cell-Based Gene Therapy; Other Gene Therapies
• 4) Other Drug Types: Utrophin Modulators; Anti-Inflammatory Agents; Antisense Oligonucleotides; Myostatin Inhibitors; Other Supportive Therapies
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Bristol-Myers Squibb; Novartis AG; GSK plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Duchenne Muscular Dystrophy Drugs Market Characteristics

3. Duchenne Muscular Dystrophy Drugs Market Trends And Strategies

4. Duchenne Muscular Dystrophy Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Duchenne Muscular Dystrophy Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Duchenne Muscular Dystrophy Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Duchenne Muscular Dystrophy Drugs Market Growth Rate Analysis
• 5.4. Global Duchenne Muscular Dystrophy Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Duchenne Muscular Dystrophy Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Duchenne Muscular Dystrophy Drugs Total Addressable Market (TAM)

6. Duchenne Muscular Dystrophy Drugs Market Segmentation

• 6.1. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exon Skipping Drugs
• Corticosteroids
• Gene Therapy
• Other Drug Types
• 6.2. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Exon Skipping Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eteplirsen
• Golodirsen
• Viltolarsen
• Casimersen
• Other Exon Skipping Therapies
• 6.5. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Deflazacort
• Other Corticosteroids
• 6.6. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Micro-dystrophin Gene Therapy
• CRISPR/Cas9-Based Gene Editing
• Stem Cell-Based Gene Therapy
• Other Gene Therapies
• 6.7. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Utrophin Modulators
• Anti-Inflammatory Agents
• Antisense Oligonucleotides
• Myostatin Inhibitors
• Other Supportive Therapies

7. Duchenne Muscular Dystrophy Drugs Market Regional And Country Analysis

• 7.1. Global Duchenne Muscular Dystrophy Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Duchenne Muscular Dystrophy Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market

• 8.1. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Duchenne Muscular Dystrophy Drugs Market

• 9.1. China Duchenne Muscular Dystrophy Drugs Market Overview
• 9.2. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Duchenne Muscular Dystrophy Drugs Market

• 10.1. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Duchenne Muscular Dystrophy Drugs Market

• 11.1. Japan Duchenne Muscular Dystrophy Drugs Market Overview
• 11.2. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Duchenne Muscular Dystrophy Drugs Market

• 12.1. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Duchenne Muscular Dystrophy Drugs Market

• 13.1. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Duchenne Muscular Dystrophy Drugs Market

• 14.1. South Korea Duchenne Muscular Dystrophy Drugs Market Overview
• 14.2. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Duchenne Muscular Dystrophy Drugs Market

• 15.1. Western Europe Duchenne Muscular Dystrophy Drugs Market Overview
• 15.2. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Duchenne Muscular Dystrophy Drugs Market

• 16.1. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Duchenne Muscular Dystrophy Drugs Market

• 17.1. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Duchenne Muscular Dystrophy Drugs Market

• 18.1. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Duchenne Muscular Dystrophy Drugs Market

• 19.1. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Duchenne Muscular Dystrophy Drugs Market

• 20.1. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Duchenne Muscular Dystrophy Drugs Market

• 21.1. Eastern Europe Duchenne Muscular Dystrophy Drugs Market Overview
• 21.2. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Duchenne Muscular Dystrophy Drugs Market

• 22.1. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Duchenne Muscular Dystrophy Drugs Market

• 23.1. North America Duchenne Muscular Dystrophy Drugs Market Overview
• 23.2. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Duchenne Muscular Dystrophy Drugs Market

• 24.1. USA Duchenne Muscular Dystrophy Drugs Market Overview
• 24.2. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Duchenne Muscular Dystrophy Drugs Market

• 25.1. Canada Duchenne Muscular Dystrophy Drugs Market Overview
• 25.2. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Duchenne Muscular Dystrophy Drugs Market

• 26.1. South America Duchenne Muscular Dystrophy Drugs Market Overview
• 26.2. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Duchenne Muscular Dystrophy Drugs Market

• 27.1. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Duchenne Muscular Dystrophy Drugs Market

• 28.1. Middle East Duchenne Muscular Dystrophy Drugs Market Overview
• 28.2. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Duchenne Muscular Dystrophy Drugs Market

• 29.1. Africa Duchenne Muscular Dystrophy Drugs Market Overview
• 29.2. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Duchenne Muscular Dystrophy Drugs Market Competitive Landscape And Company Profiles

• 30.1. Duchenne Muscular Dystrophy Drugs Market Competitive Landscape
• 30.2. Duchenne Muscular Dystrophy Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis

31. Duchenne Muscular Dystrophy Drugs Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Aurobindo Pharma Limited
• 31.3. Italfarmaco S.p.A
• 31.4. Sarepta Therapeutics Inc.
• 31.5. PTC Therapeutics Inc.
• 31.6. FibroGen Inc.
• 31.7. Wave Life Sciences Ltd.
• 31.8. Solid Biosciences Inc.
• 31.9. NS Pharma
• 31.10. Capricor Therapeutics Inc.
• 31.11. Santhera Pharmaceuticals
• 31.12. ReveraGen BioPharma
• 31.13. Antisense Therapeutics Limited
• 31.14. Catalyst Pharmaceuticals Inc.
• 31.15. EspeRare Foundation

32. Global Duchenne Muscular Dystrophy Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Drugs Market

34. Recent Developments In The Duchenne Muscular Dystrophy Drugs Market

35. Duchenne Muscular Dystrophy Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Duchenne Muscular Dystrophy Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Duchenne Muscular Dystrophy Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Duchenne Muscular Dystrophy Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer